
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Jaguar Animal Health Inc (JAGX)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: JAGX (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $28
1 Year Target Price $28
1 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.84% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.96M USD | Price to earnings Ratio - | 1Y Target Price 28 |
Price to earnings Ratio - | 1Y Target Price 28 | ||
Volume (30-day avg) 2 | Beta 0.44 | 52 Weeks Range 1.93 - 35.25 | Updated Date 08/15/2025 |
52 Weeks Range 1.93 - 35.25 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -60.27 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -425.52% |
Management Effectiveness
Return on Assets (TTM) -37.48% | Return on Equity (TTM) -459.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 36608870 | Price to Sales(TTM) 0.34 |
Enterprise Value 36608870 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 3.17 | Enterprise Value to EBITDA -0.63 | Shares Outstanding 1914430 | Shares Floating 990679 |
Shares Outstanding 1914430 | Shares Floating 990679 | ||
Percent Insiders 8.15 | Percent Institutions 4.56 |
Upturn AI SWOT
Jaguar Animal Health Inc

Company Overview
History and Background
Jaguar Animal Health Inc. was a commercial stage animal health company focused on developing and commercializing novel, prescription pharmaceuticals derived from sustainably harvested plants from rainforest regions. It appears to have ceased operations or significantly altered its business model as it is no longer actively trading under its previous ticker symbol.
Core Business Areas
- Pharmaceuticals for Animals: Development and commercialization of prescription pharmaceuticals for gastrointestinal and inflammatory disorders in animals, particularly focused on dogs and horses.
Leadership and Structure
Information regarding the specific leadership and organizational structure prior to ceasing operations is difficult to obtain. Public information would be required to discern specific roles.
Top Products and Market Share
Key Offerings
- Canaleviau00ae: A drug approved for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Market share data is unavailable due to the company's current status. Competitors for anti-diarrheal medications in dogs include Zoetis and Boehringer Ingelheim.
- Neonormu2122 Calf: A product indicated for the supportive treatment of diarrhea in calves. Market share data is unavailable. Competitors include companies offering electrolyte and antibiotic treatments for calf diarrhea.
Market Dynamics
Industry Overview
The animal health industry is a growing market driven by increasing pet ownership, rising disposable incomes, and a greater focus on animal welfare. The pharmaceutical segment is competitive, with established players and emerging companies.
Positioning
Prior to ceasing active operations, Jaguar Animal Health aimed to carve a niche with plant-derived pharmaceuticals. The advantage would have been the natural derivation. The disadvantage being the competition from large, established players.
Total Addressable Market (TAM)
TAM estimates for the animal health pharmaceutical market vary depending on the specific segment (e.g., companion animals vs. livestock). The overall TAM is in the tens of billions of dollars. Given Jaguar's niche focus, their potential TAM would have been a smaller fraction of this total. Positioned to address gastrointestinal disorders.
Upturn SWOT Analysis
Strengths
- Novel plant-based pharmaceuticals
- Potential for a natural/organic brand image
- Approved products for specific indications
Weaknesses
- Limited financial resources
- Small market share compared to major players
- Dependence on single product lines
Opportunities
- Expanding distribution channels
- Developing new indications for existing products
- Strategic partnerships or acquisitions
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles for new drug approvals
- Potential for generic versions of existing products
Competitors and Market Share
Key Competitors
- ZOET (Zoetis Inc.)
- MRK (Merck & Co., Inc.)
- BMY (Bristol-Myers Squibb)
Competitive Landscape
Jaguar Animal Health was at a disadvantage compared to established players with greater resources and wider product portfolios. Its niche focus and plant-based approach provided some differentiation, but ultimately, it was not enough to sustain the business.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was limited due to financial constraints and competitive pressures.
Future Projections: Future projections are not applicable.
Recent Initiatives: Recent strategic initiatives are unknown.
Summary
Jaguar Animal Health faced significant challenges in a competitive market, struggling to achieve sustainable growth and profitability. It aimed to leverage plant-derived pharmaceuticals but ultimately couldn't compete with larger, more established players. Financial difficulties and competitive pressures contributed to its current state. The company will have to overcome fundamental structural difficulties. Due Diligence is required to determine the reason for failure.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Public filings (historical)
- Industry reports
- Company websites (historical)
Disclaimers:
The information provided is based on available data and may not be entirely accurate due to the company's status. This is not financial advice. Conduct thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jaguar Animal Health Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2015-05-13 | Founder, CEO, President & Director Ms. Lisa A. Conte | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://jaguar.health |
Full time employees 49 | Website https://jaguar.health |
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. The company operates through two segments, Animal Health and Human Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company offers Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase III clinical trial for prophylaxis of diarrhea in adult cancer patients; Phase II clinical trials for rare/orphan disease indications, including short bowel syndrome with intestinal failure and microvillus inclusion disease; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing Mytesi which is in Phase III clinical trial for cancer therapy-related diarrhea, as well as Phase II clinical trial for irritable bowel syndrome; and NP-300, a second-generation antidiarrheal drug that is in Phase I clinical trial for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.